UAS
NRXP icon

United Asset Strategies’s NRX Pharmaceuticals NRXP Stock Holding History

United Asset Strategies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,830
Closed -$8.64K – 240
2024
Q1 		$8.64K Hold
1,830
– – ﹤0.01% 234
2023
Q4 		$8.42K Hold
1,830
– – ﹤0.01% 234
2023
Q3 		$4.76K Hold
1,830
– – ﹤0.01% 229
2023
Q2 		$8.85K Hold
1,830
– – ﹤0.01% 228
2023
Q1 		$12.1K Hold
1,830
– – ﹤0.01% 221
2022
Q4 		$20.3K Hold
1,830
– – ﹤0.01% 224
2022
Q3 		$14K Hold
1,830
– – ﹤0.01% 205
2022
Q2 		$11K Hold
1,830
– – ﹤0.01% 205
2022
Q1 		$45K Buy
+1,830
New +$59.5K 0.01% 205

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

United Asset Strategies's NRXP Position: Q2 2024 in Review

United Asset Strategies sold out of NRX Pharmaceuticals (NRXP) in Q2 2024, closing a stake of 1,830 shares — an estimated $8.64K sold.

United Asset Strategies first reported a position in NRXP in Q1 2022 and held it in 9 quarters. The position peaked at $45K in Q1 2022. 19 funds tracked by Wall St. Rank hold NRXP as of Q2 2024.

  • United Asset Strategies reported no remaining NRX Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • United Asset Strategies sold 1,830 NRX Pharmaceuticals shares in Q2 2024, an estimated $8.64K.
  • United Asset Strategies first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • United Asset Strategies's NRX Pharmaceuticals position peaked at $45K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2024.

Based on United Asset Strategies's 13F filing for Q2 2024, filed 1 Aug 2024.